+44 7868 792050
Wayne Grant Carter
Division of Medical Sciences and Graduate Entry Medicine, School of Graduate
Entry Medicine & Health University of Nottingham, Medical School Royal Derby Hospital, UK
Dr. Wayne Grant Carter received his Honours degree in Biochemistry with Nutrition from the University of Southampton. He then completed a PhD at the University of Southampton studying the molecular signalling cascade elicited by insulin. His PhD studies encompassed the design and synthesis of peptide targets for insulin stimulated kinases and their utilisation to dissect signalling events downstream of insulin binding to its receptor. He purified peptide targets by reverse phase high performance liquid chromatography RPHPLC and assayed signalling kinases utilising radiolabelled phosphorus to determine phosphorylation sites by both radiosequencing and phosphopeptide mapping eg Carter et al 1995-1996. Subsequent postdoctoral studies at the Babraham Institute Cambridge; Imperial College London; University of California at Irvine; and University of Oxford were also directed toward the regulation of cellular signalling mechanisms through posttranslational modification of proteins and how these influence inflammation and homeostasis. Dr. Carter then spent one year working for Mobious Genomics Exeter assisting with the biophysical development of novel DNA sequencing devices before he joined the staff at the University of Nottingham where he is currently a Principal Investigator and Lecturer for a new course in Healthcare Sciences founded at the University of Nottingham site within the Royal Derby Hospital Derby. His previous and current research pioneered the use of proteomic techniques coupled to novel imaging of radiolabels to detect and purify proteins that are modified posttranslationally eg Vigneswara et al 2006; Carter et al 2007; Tarhoni et al 2008; Carter Aswad 2008; Kharbanda et al 2009; Carter et al 2010. He has received external grant funding for his academic studies from research funding bodies that include the Wellcome Trust UK and the National Institutes of Health USA and also from commercial sources that include Syngenta UK. His professional affiliations include The Physiological Society the Royal Society of Chemistry the Biochemical Society the British Toxicological Society the British Neuroscience Association and the American College of Sports Medicine.
Purified peptide targets by reverse-phase high performance liquid chromatography (RP-HPLC), and assayed signalling kinases utilising radiolabelled phosphorus to determine phosphorylation sites by both radiosequencing and phosphopeptide mapping. Use of proteomic techniques coupled to novel imaging of radiolabels to detect and purify proteins that are modified post-translationally.